FDA Approves DBS Neurostimulation System With Brain Signal Tracking

The Food and Drug Administration (FDA) has approved the Percept™ PC Deep Brain Stimulation (DBS) system (Medtronic) with BrainSense™ technology for neurological disorders.

Percept PC DBS system is a small pacemaker-like device implanted under the skin of the chest or abdomen that delivers electrical stimulations through leads to a targeted area in the brain. The system features BrainSense technology that captures and records brain signals while delivering therapy to patients with Parkinson disease, essential tremor, dystonia, epilepsy or obsessive-compulsive disorder. 

Physicians will be able to individualize treatment using the DBS clinician programmer, while patients have the ability to customize therapy to their desired activities using the patient programmer. The DBS system also includes expanded MRI eligibility (3T and 1.5T full body MRI scans), a smart battery for personalized prediction of remaining battery life, improved battery longevity with a smaller design for patient comfort, and low pulse width to expand stimulation options. 

The Mayo Clinic in Rochester, Minnesota, will be the first to implant the new device in the US. “Our goal is for patients to regain independence, and we know that DBS can significantly improve motor function in people with Parkinson disease compared to standard medication alone,” said Bryan Klassen, MD, neurologist, Mayo Clinic. “We can now more precisely tailor therapy to the individual needs of each patient based on data from neuronal activity.”

For more information visit medtronic.com.